Search research articles
Contact Us
Filters
Showing results (61-70 of 76) with videos related to
Page
of 8
Sort By:
Acta Neuropathologica Communications
|
February 16, 2019
A walk through tau therapeutic strategies
Santosh Jadhav, Jesus Avila, Michael Schöll, et al.
Acta Neuropathologica Communications
|
April 4, 2024
Shaping the future of preclinical development of successful disease-modifying drugs against Alzheimer's disease: a systematic review of tau propagation models
Neha Basheer, Luc Buee, Jean-Pierre Brion, et al.
Alzheimer'S Research & Therapy
|
November 23, 2024
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217
Branislav Kovacech, Nicholas C Cullen, Petr Novak, et al.
Acta Neuropathologica Communications
|
May 31, 2020
Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation
Monika Zilkova, Anna Nolle, Branislav Kovacech, et al.
Scientific Reports
|
November 2, 2018
3D MALDI mass spectrometry imaging reveals specific localization of long-chain acylcarnitines within a 10-day time window of spinal cord injury
Jusal Quanico, Lena Hauberg-Lotte, Stephanie Devaux, et al.
Scientific Reports
|
August 20, 2024
Brain of miyoshi myopathy/dysferlinopathy patients presents with structural and metabolic anomalies
Petra Hnilicova, Marian Grendar, Monika Turcanova Koprusakova, et al.
Neurology
|
September 25, 2020
Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias
Jozef Hanes, Andrej Kovac, Hlin Kvartsberg, et al.
Alzheimer'S Research & Therapy
|
October 26, 2018
FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease
Petr Novak, Reinhold Schmidt, Eva Kontsekova, et al.
The Lancet. Neurology
|
December 14, 2016
Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial
Petr Novak, Reinhold Schmidt, Eva Kontsekova, et al.
The Journal of Prevention of Alzheimer'S Disease
|
January 12, 2025
Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease
Sandar Aye, Gunilla Johansson, Christoph Hock, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 76) with videos related to
Sort By:
Page
of 8
Acta Neuropathologica Communications
|
February 16, 2019
A walk through tau therapeutic strategies
Santosh Jadhav, Jesus Avila, Michael Schöll, et al.
Acta Neuropathologica Communications
|
April 4, 2024
Shaping the future of preclinical development of successful disease-modifying drugs against Alzheimer's disease: a systematic review of tau propagation models
Neha Basheer, Luc Buee, Jean-Pierre Brion, et al.
Alzheimer'S Research & Therapy
|
November 23, 2024
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217
Branislav Kovacech, Nicholas C Cullen, Petr Novak, et al.
Acta Neuropathologica Communications
|
May 31, 2020
Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation
Monika Zilkova, Anna Nolle, Branislav Kovacech, et al.
Scientific Reports
|
November 2, 2018
3D MALDI mass spectrometry imaging reveals specific localization of long-chain acylcarnitines within a 10-day time window of spinal cord injury
Jusal Quanico, Lena Hauberg-Lotte, Stephanie Devaux, et al.
Scientific Reports
|
August 20, 2024
Brain of miyoshi myopathy/dysferlinopathy patients presents with structural and metabolic anomalies
Petra Hnilicova, Marian Grendar, Monika Turcanova Koprusakova, et al.
Neurology
|
September 25, 2020
Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias
Jozef Hanes, Andrej Kovac, Hlin Kvartsberg, et al.
Alzheimer'S Research & Therapy
|
October 26, 2018
FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease
Petr Novak, Reinhold Schmidt, Eva Kontsekova, et al.
The Lancet. Neurology
|
December 14, 2016
Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial
Petr Novak, Reinhold Schmidt, Eva Kontsekova, et al.
The Journal of Prevention of Alzheimer'S Disease
|
January 12, 2025
Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease
Sandar Aye, Gunilla Johansson, Christoph Hock, et al.
Page
of 8